The Finsbury Worldwide Pharmaceutical trust has cut its gearing by almost half over the six months t...
The Finsbury Worldwide Pharmaceutical trust has cut its gearing by almost half over the six months to 30 September, reducing the drawdown on its loan facility from £50m to £27m. The the trust's interim results show NAV per share declined from 557.6p to 342.6p over the review period. Chairman Sir Stuart Burgess said revenue generated from the company's investments continues to be modest and no interim dividend is being declared. He said the board will declare dividends only to the extent required to maintain investment trust status.
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
